[{"from": "human", "value": "What can you tell me about this molecule? [C][C@@H1][Branch2][Branch1][#Branch2][C@H1][Branch2][Ring2][Ring1][C@@H1][Branch2][Ring1][=C][C@H1][Branch1][Branch1][C@@H1][Ring1][=Branch1][N][O][C@@H1][C@@H1][Branch1][P][C@H1][Branch1][=N][C@@H1][Branch1][=Branch2][C@H1][Branch1][Ring2][O][Ring1][=Branch1][C][O][O][N][O][O][O][C@@H1][C@@H1][Branch1][=C][C][C@@H1][Branch1][=Branch2][C@H1][Branch1][Ring2][O][Ring1][=Branch1][C][N][O][N][N]"}, {"from": "gpt", "value": "The molecule are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as \u03b2-lactams and cephalosporins.  Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic)."}]